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Introduction
The introduction of IGRAs to clinical practice 
enabled to improve the diagnostic accuracy of latent 
tuberculosis infection (LTBI). The assessment of LTBI 
by IGRAs is based on response to specific antigens: 
early secreted antigenic target 6 kDa (ESAT-6) and 
culture filtrate protein 10 kDa (CFP-10), localized in 
a specific genomic area of Mycobacterium tuberculosis, 
called the region of difference (RD1) (Borkowska 2011; 
Demkow 2011).
Subsequently, IGRAs have been extensively used 
to diagnose LTBI in susceptible populations, among 
others, persons after active tuberculosis contact, immu-
nocompromised hosts, and the candidates to immuno-
suppressive therapy, especially to anti-TNF alfa treat-
ment (Borkowska et al. 2011; Demkow 2011).
The overall prevalence of LTBI in different countries 
is closely related to tuberculosis (Tb) burden; thus, the 
countries with high Tb burden would have more LTBI 
cases diagnosed with IGRAs and those with low Tb 
burden – less such cases (Kuś et al. 2011).
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A b s t r a c t
Interferon gamma releasing assays (IGRAs) are extensively used in the diagnosis of latent tuberculosis infections. Comparing to tuberculin 
skin test (TST) they lack false positive results in the populations vaccinated with BCG, and in most non-tuberculous mycobacteria (NTM) 
infections. Nevertheless, Mycobacterium kansasii, Mycobacterium marinum, and Mycobacterium szulgai may induce positive IGRAs due 
to RD1 homology with Mycobacterium tuberculosis. The aim of the study was to investigate the possible influence of NTM respiratory 
isolates on the results of IGRAs. 39 patients (23 females and 16 males) of median age 61 years, with negative medical history concerning 
tuberculosis, entered the study. Identification of NTM was performed using the niacin test and molecular method GenoType CM test 
(Hain Lifescience). QFT-Plus was performed in 17 patients, T-SPOT-Tb – in 23 patients. Chest X-rays and a high-resolution computed 
tomography of the chest have been reviewed by the experienced radiologist blinded to the results of IGRAs, in search of past tuberculosis 
signs. Positive IGRAs results were obtained in three out of 39 patients (8%): 22% of patients with M. kansasii isolates and 18% of patients 
with radiological signs on HRCT that might be suggestive of past tuberculosis. Positive IGRAs correlated with radiological signs suggestive 
of past tuberculosis (r = 0.32, p = 0.04), and on the borderline with isolation of M. kansasii (r = 0.29, p = 0.06). These findings may suggest 
that a positive IGRAs result, in our material, could depend mostly on asymptomatic past Tb infection. The cross-reactivity of M. kansasii 
isolates with IGRAs was less probable; nevertheless, it requires further investigations.
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The superiority of IGRAs over tuberculin skin test 
(TST) in LTBI diagnostic pathway, is related to its higher 
specificity, e.g. lack of false positive results in the popu-
lations vaccinated against M. tuberculosis and those 
infected with most of non-tuberculous mycobacteria 
(NTM) (Demkow 2011; Kuś et al. 2011; Mancuso et al. 
2012). Nevertheless, some NTM, such as Mycobacte-
rium kansasii, Mycobacterium marinum and Mycobac-
terium szulgai share RD1 with M. tuberculosis and could 
induce false positive immunological response assessed 
by IGRAs (Demkow 2011). This observation may be 
important, especially in the countries with low Tb bur-
den, defined by European Centre for Disease Preven-
tion and Control experts as notification rate lower than 
20 per 100 000 population (ECDC/WHO 2018), and 
with increased incidence of diseases caused by NTM 
(Prevots et al. 2010). In Poland, as well as in Slovakia 
and in the United Kingdom, a large proportion of NTM 
infections have been caused by M. kansasii, possibly 
influencing the specificity of IGRAs in LTBI diagnostics 
(Słupek et al. 1997; Hoefsloot et al. 2013; van der Werf 
et al. 2014; Wilińska et al. 2014; Bakuła et al. 2018).
Thus, the aim of the present study was to investi-
gate the influence of NTM isolation from respiratory 
specimens on the results of IGRAs in patients with no 
medical history of tuberculosis.
Experimental
Materials and Methods
Patients. Overall, 39 patients (23 females and 
16 males) of median age 61 years (27–85 years), from 
whom NTM was cultured from respiratory specimens 
(sputum and/or bronchial washings) in the period 
of 2010–2017, and IGRA test was performed simul-
taneously, entered the study. Patients, who had been 
diagnosed and treated for tuberculosis, were excluded 
from the study.
Non-tuberculous mycobacterial lung disease 
(NTMLD) was recognized in 16 patients according to 
American Thoracic Society/Infectious Diseases Society 
of America (ATS/IDSA) and recent British Thoracic 
Society recommendations (Griffith et al. 2007; Haworth 
et al. 2017). In 23 patients, respiratory isolates did not 
cause the disease. The characteristic of the population 
is summarized in Table I.
Chest X-rays and high resolution computed tomo-
graphy (HRCT) of the chest were reviewed by the 
experienced radiologist blinded to the results of IGRAs 
in search of fibrotic foci localized in the upper lobes 
or upper parts of lower lobes, as well as parenchymal 
and lymph nodes’ calcifications.
Methods of NTM culture and identification. The 
specimens were digested with the sodium hydroxide 
and N-acetyl-L-cysteine (NaOH/NALC) method. After 
decontamination, the sample was neutralized with 
sterile phosphate buffer (pH  6.8) and centrifuged at 
3000 × g for 15 min. The pellet was suspended in 2 ml 
of phosphate buffer. The strains were cultured on solid 
media: egg-based L-J medium, Stonebrink medium 
and in automated system MGIT (Becton Dickinson) 
(Klatt et al. 2015).
Identification of culture was performed using the 
niacin test and a molecular method GenoType CM 
test (Hain Lifescience). The GenoType CM test, using 
the DNA-STRIP method allowed the identification of 
M. tuber culosis complex strains and 14 clinically rele-
vant NTM within a single procedure. The procedure 
for identifying strains consists of three steps: isola-
tion of DNA, amplification using primers labeled with 
biotin and a reverse hybridization. This hybridiza-
tion reaction includes the consecutive steps: chemi-
cal denaturation of the amplification products, hybri-
dization of single-stranded amplicons labeled with 
biotin on a membrane coated with probes, washing, 
adding streptavidin/alkaline phosphatase conjugate, 
staining reaction using alkaline phosphatase (Zabost 
and Augustynowicz-Kopeć 2015).
Molecular detection of M. tuberculosis. Identifica-
tion using the BD ProbeTec ET system (Becton Dickin-
son Diagnostic Instruments) was performed accord-
ing to the manufacturer’s instructions. The instrument 
Males 16 58.5 (28–75) 24.9 (19.5–38.9) 5 3 0 0 3 5
Females 23 62 (29–85) 23.8 (16.2–37.3) 5 6 4 2 2 4
Total 39 61 (27–85) 24.3 (15–38.9) 10 9 4 2 5 9
Table I
Characteristics of the population of patients, from whom NTM was isolated from respiratory specimens.
COPD – chronic obstructive pulmonary disease; ILD – interstitial lung disease; GPA – granulomatosis with polyangiitis;
CTD – connective tissue disease; CF – cystic fibrosis; npl – neoplasm; BMI – body mass index
* Diabetes (2), hypothyreosis (1), lung aspergilloma (1), renal insufficiency (1), bronchiectasis (2),
 actinomycosis (1), lung cirrhosis (1), lobar pulmonary artery agenesis (1), trombofilia (1)
Sex Noof pts
Age Median
(range)
BMI Median
(range)
Number of patients with certain coexisting disease
COPD ILD or GPA CTD CF Npl Others*
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reported amplification signals > 3 500 method-other-
than-acceleration (MOTA) units as positive (Klatt 
2015). It was performed in all cases with a positive 
result of direct bacterioscopy.
Interferon gamma release assays. The IGRAs assays 
identified cellular immune responses to M. tuberculosis 
by measuring interferon-gamma (IFN-γ) after stimula-
tion of T cells with M. tuberculosis-specific antigens. 
Two tests were available: T-SPOT.TB based on the 
Elispot-enzyme-linked immuno spot and Quanti- 
Feron TB Gold Plus (QFT-Plus) based on the enzyme-
linked immunosorbent assays (ELISA) technique. 
The T-SPOT.TB test is based on measurement of the 
number of peripheral mononuclear cells that produce 
IFN-γ after stimulation with two antigens: ESAT-6 and 
CFP 10. The antigens used in QFT-Plus consisted of 
a peptide cocktail simulating the ESAT-6 and CFP 10 
(Borkowska et al. 2017).
QFT-Plus was performed in 17 patients, T-SPOT-Tb 
– in 23 (including one patient, in whom both IGRAs 
have been performed).
Statistical analysis. The data were presented as medi-
ans and ranges or as number and percentage of posi- 
tive cases. The differences between categorical variables 
were analyzed with the chi-square test, for quantitative 
variables – ANOVA test was used. The correlation was 
assessed with Spearman rank order test. P < 0.05 was 
considered statistically significant.
Results
Positive IGRAs results were obtained in three out 
of 39 patients (8%): positive QFT Plus – in two cases, 
T-SPOT-TB – in one case. In one patient, in whom 
both tests were performed, T-SPOT-Tb was negative 
but QFT was positive.
IGRAs results according to the identified type of 
NTM were shown in Table II. Positive results were 
obtained in 2/9 (22%) of patients with M. kansasii and 
one patient with M. fortuitum isolate. IGRAs positivity 
was thus found in 2/10 (20%) of NTM sharing the RD1 
region with M. tuberculosis (M. kansasii, M. szulgai) and 
1/29 (3%) of those without RD1 sharing (p = 0.31).
Positive IGRAs were obtained in 2/23 females (9%) 
and 1/16 males (6%), (p = 0.91).
IGRAs results according to the patients’ age 
(Table III) revealed that positive results were found only 
in the patients above 60 years of age; nevertheless, the 
age-related differences were not significant (p = 0.49).
HRCT analysis revealed the presence of lesions sug-
gesting the possibility of the previous infection with 
M. tuberculosis in 17/39 (44%) of patients.
The results of IGRAs according to the results of 
radiological analysis are shown in Table IV. Positive 
IGRAs were found in 3/17 (18%) patients with the 
above-mentioned radiological signs and none of the 
remaining patients (p = 0.15).
Positive IGRAs results correlated with radiologi-
cal signs suggestive of possibility of infection with 
M. tuberculosis in the past (r = 0.32, p = 0.04); the corre-
lation of positive IGRA with the isolation of M. kansasii 
was borderline (r = 0.29, p = 0.06).
Discussion
Positive IGRAs have been found in three (8%) of 
patients with NTM cultured from respiratory speci-
mens. Two positive IGRAs results concerned the 
patients with M. kansasii isolates (22%), the species 
sharing RD1 with M. tuberculosis, one – the patient with 
M. fortuitum isolate, the species not sharing RD1. The 
Japanese studies revealed IGRAs positivity in 19–52% 
of M. kansasii isolates (Kobashi et al. 2009; Sato et al. 
M. kansasii 2 (22%) 7 9
M. avium 0 7 7
M. gordonae 0 6 6
M. chimaera 0 5 5
M. xenopi 0 5 5
M. fortuitum 1 (33%) 2 3
M. szulgai 0 1 1
M. abscessus 0 1 1
M. mucogenicum 0 1 1
M. smegmatis  0 1 1
Total 3 (8%) 36 39
Table II
IGRAs results according to the NTM species.
Species TotalIGRA (–)IGRA (+)
IGRAs (+) 0 0 0  3 (14%) 3
IGRAs (–) 0 11 8 17 36
Total 0 11 8 20 39
Table III
IGRAs result according to patients’ age.
Age (years) Total≥ 6045–5925–44≤ 24
Past tb signs 3 (18%) 14 (82%) 17
No past tb signs 0 (0%) 22 22
Total 3 36 39
Table IV
The IGRAs results according to radiologic signs
of past tuberculosis.
CT – computed tomography, tb – tuberculosis
TotalIGRA (–)IGRA (+)Chest CT
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2016). The European experience is scarce; nevertheless, 
Hermansen et al. (2014) found positive IGRAs results 
in 2/2 M. kansasii isolates (100%).
The discrepancies concerning IGRAs positivity 
were found also in M. avium/M. intracellulare (MAC) 
infection: from 0–8% positive results in the studies 
conducted in Northern Europe and Japan (Adams 
et al. 2008; Kobashi et al. 2009; Hermansen et al. 2014) 
to 34% in the study conducted in South Korea (Ra et al. 
2011). In our study, all seven cases of M. avium isolates 
were IGRAs negative. As MAC doesn’t share the RD1 
region with M. tuberculosis, positive IGRAs obtained 
for the patients with MAC isolates by other authors 
might reflect the background influence of past tuber-
culosis, especially in countries with high Tb burden (Ra 
et al. 2011; Wang et al. 2016).
Poland belongs to low Tb burden countries, with the 
incidence rate of tuberculosis calculated as 19.7/100 000 
in 2010 and 15.1/100 000 in 2017 (Korzeniewska-
Koseła 2017, 2018). The analysis of LTBI prevalence 
assessed with QFT, performed in 2010 on 621 healthy 
subjects from Mazowieckie province, revealed the posi-
tive results in 23.3% of them, more frequently in older 
people compared to younger ones (Kuś et al. 2011). 
Positive IGRAs in the present study were found exclu-
sively in patients > 60 years of age, indicating possible 
influence of background non-recognized Tb infection 
in the past on the results obtained.
Retrospective analysis of HRCT scans by an expe-
rienced radiologist blinded to IGRAs results, revealed 
the lesions suggestive of possibility of infection with 
M. tuberculosis in the past in 17 out of 39  patients 
(44%), despite lack of Tb in anamnesis. Positive IGRAs 
were noted in three out of 17 patients with radiological 
signs suggestive of past tuberculosis (18%) and none of 
the patients without such findings on chest CT scan.
These findings may suggest that positive IGRAs 
result, in our material, could depend mostly on 
asymptomatic past Tb infection. The cross-reactivity 
of M. kansasii isolates with IGRAs is less probable, 
because it was present only in two out of nine patients 
with M. kansasii isolates.
The same type of analysis has been performed by 
Sato et al. who found T-SPOT positivity in 33% of 
patients with M. kansasii isolates, but after exclusion 
of those with a history of tuberculosis (defined as either 
Tb diagnosis and treatment in the past or chest X-ray 
features suggesting previous tuberculosis), the per-
centage of T-SPOT positive cases decreased to 19%. 
They concluded that features of previous Tb are the 
only risk factor for positive IGRAs in the patients with 
M. kansasii respiratory isolates.
Since the group of patients was small in the cur-
rent study, further studies are required to answer the 
question, whether the positive IGRAs in patients with 
M. kansasii isolates is caused by RD1 cross-reactivity 
or rather the background of asymptomatic tuberculosis 
in the past.
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